Switzerland-based Novartis (NYSE: NVS) subsidiary Sandoz has bolstered its global anti-infectives portfolio with the acquisition of Mycamine/Funguard (micafungin sodium) from Japan’s Astellas Pharma (TYO: 4503). Mycamine is the highest-selling antifungal of the echinocandin class, and while the transaction amount was not disclosed, the product generated JPY 14.2 billion (USD 105 million) in sales during the Japanese fiscal year 2022-2023.
Mycamine’s Therapeutic Indications and Global Patient Base
The medicine is indicated for the treatment of invasive candidiasis and esophageal candidiasis, as well as for the prevention of candida and aspergillus infections in patients undergoing hematopoietic stem cell transplantation. Mycamine’s patient base exceeds 2 million globally, making it a therapy of choice for healthcare professionals.
Building on Previous Acquisitions
The acquisition follows Sandoz’s 2021 purchase of the cephalosporins portfolio from UK firm GlaxoSmithKline (GSK, NYSE: GSK). This strategic move by Sandoz underscores its commitment to expanding its anti-infective offerings and enhancing its position in the global pharmaceutical market.-Fineline Info & Tech
